多西他赛联合洛铂治疗蒽环类耐药的晚期乳腺癌疗效分析.pdf

多西他赛联合洛铂治疗蒽环类耐药的晚期乳腺癌疗效分析张null彦1,刘英光2,孙null红1ClinicalobservationofdocetaxelpluslobaplatinintreatinganthracyclinesresistantadnullvancedbreastcancerZHANGYan1,LIUYing-guang2,SUNHong11DepartmentofQncology,QingdaoMunicipalHospital,Qingdao266011,China；2DepartmentofGynaecology,PingduPeoplesHospital,Pingdu,266700,China.nullAbstractnullObjective:Toobservethecurativeeffectandtoxicityofdocetaxelpluslobaplatininadvancedbreastcancerpatientswhoweredrugfastinusinganthracenenucleusdrugs.Methods:Fortytwofemalepatientsreceiveddocetaxel75mg/m2ondlandlobaplatin30mg/m2ond1ofevery21days.Everypatientwasadministeredatleast2cycles.Results:Fourpatientsachievedcompleteresponseand19partialresponse,theoverallresponseratewas54.8%,oneyearsurvivalratewas64.2%,themainsideeffectwasmarrowsurpression.Conclusion:Combinedchemotherapyofdocetaxelandlobaplatinhasagoodanti-tumoractivityandmanageabletoxicityonadvancedbreastcancerpatientswhoweredrugfastinusinganthracenenucleusdrugs.nullKeywordsbreastcancer；docetaxe；llobaplatin；combinedchemotherapyModernOncology2011,19(03):0473-0474nullK1null:4sZx00F5r#TbZE:sZF42b75mg/m21?,s30mg/m21?b21?,2bT:42,CRaPRsY4a19,9rq54.8%(23/42),1M3iq64.3%(27/42),1Qb:sZx00Frz,Q,x00FzZbnull1oMF；snullms|R737.9nullnullnullnullDSMAnullnullnullnullDOI:10.3969/.jissn.1672-4992.2011.03.22nullcI|1672-4992-(2011)03-0473-02nullnullcxZ-FBLZ,x0F,-SZb=L0,a=a5sb12006M6,sZF42,C|T/b1nullZE1.1nullh4hLF,M-70s,93iV3；-/?a?am,V5CTaMRI?4S,v%hbF(x0F,:(1)cx0Z6=CMnulllnull2010-07-05nullnull2010-08-31nullTnull1ggD?S,nullnull2660112gDS,nullnull266700nullTenullf(1974-),o,D=,V,1VYF8bnullYTnull(1965-),o,D=,1VY?=SbE-mai:?；(2)Fcx0Z2rb1.2nullB12006M6-2008M1lx00F42,(o,M-S24-6O,M-48b-18(42.9%),24(57.1%)b?1(F,MCTaMRI,%M37a(FaC)?16akM11aM7a7M11aM13,B)F2M29,)M10,)3；s8(ER/PR)27,|14,W1；HER-2/neus8HWbQWHOQSs0-IVb2nullT2.1null5rsZ42h,134,(h3.2bhVN,CR4,PR19,SD11,PD8,rq54.8%(23/42),1M3iq64.3%(27/42)b2.2nullQZ1Q(VI,AKn,lhbdA(,n0a|s#,#a#a/#(1n,M1b8nV1bV1nulls42FQTab.1nullAdverseeventsoccurredinthe42advancedbreastcancerpanulltientsaftertreatmentwithdocetaxelpluslobaplatinAdverseeventsGrade0Grade#Grade!GradeGrade%leucocytopenia1471371thrombopenia1112973nausea/vomit8191230liverdisfunction345300kidneydisfunction392100heartdisfunction411000fatigue927510alopecia03523113null)cx0ZXF-a#MFSZ,x00,5CS=LZbMF1ZEb,0FKr0BbB,F?0bYV5,55i,P5Ah,V7%s9bDV,T=L0,0VF3i,Orc1bssF0,F?TYVPt-GGPt-AG=,EDNAcV,V7?%2bsM1,sA/,1,*a9hQ(1s,4Klh,5sM3b5-AU,sFs5sbs0?MFrq45.2%4,as=Frq42.4%5b1sx00F,S=16bFT4U,sx00Fzr,rq54.8%,1M3iq64.3%,Q,1ilh,l/,Bl,hQ,69nb9,sFZSx0?MF=L,rz,Tl,0sz,BbnullID1nullI.,?0ZMMF54J.C?D,2010,18(2):296-298.2nullSparanoJA.Taxanesforbreastcancer:anevidence-basedreviewofrandomizedphase!andphasetrialsJ.ClinBreastCancnuller,2000,1:32-40.3nullSarisCP,vandeVaartPJ,RietbroekRC,eta.lInvitroformationofDNAadductsbycisplatin,lobaplatinandoxaliplatinincalfthymusDNAinsolutionandinculturedhumancellsJ.Carcinogenesis,1996,17(12):2763-2769.4null,U|O.s5ZJ.5?,2006,11(7):549-552.5nullZ,c,),.sassY9F,1C?D,2008,16(10